FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2095297787> ?p ?o ?g. }

• W2095297787 endingPage "52130" @default.
• W2095297787 startingPage "52124" @default.
• W2095297787 abstract "Cot is a MAPK kinase kinase that has been implicated in cellular activation and proliferation. Here, we show that the addition of lipopolysaccharide (LPS) to RAW264 macrophages induces a 10-fold increase of endogenous Cot activity, measured as MAPK kinase kinase 1 activity. Taxol, but not phorbol 12-myristate 13-acetate (PMA), induces a similar activation of Cot. A tyrosine kinase activity is involved in Cot activation by LPS. 15-Deoxy-Δ12,14-prostaglandin J2, but not rosiglitazone, blocks Cot activation by LPS. Furthermore, 15-deoxy-Δ12,14-prostaglandin J2 also inhibited the LPS-induced Cot in vitro. However, 15-deoxy-Δ12,14-prostaglandin J2 does not inhibit MAPK kinase 1 or ERK1/ERK2 activation/phosphorylation induced by PMA and mediated by c-Raf. Considering these data, we propose that the inhibition of LPS-induced Cot activation is one mechanism by which 15-deoxy-Δ12,14-prostaglandin J2 acts as an anti-inflammatory. Cot is a MAPK kinase kinase that has been implicated in cellular activation and proliferation. Here, we show that the addition of lipopolysaccharide (LPS) to RAW264 macrophages induces a 10-fold increase of endogenous Cot activity, measured as MAPK kinase kinase 1 activity. Taxol, but not phorbol 12-myristate 13-acetate (PMA), induces a similar activation of Cot. A tyrosine kinase activity is involved in Cot activation by LPS. 15-Deoxy-Δ12,14-prostaglandin J2, but not rosiglitazone, blocks Cot activation by LPS. Furthermore, 15-deoxy-Δ12,14-prostaglandin J2 also inhibited the LPS-induced Cot in vitro. However, 15-deoxy-Δ12,14-prostaglandin J2 does not inhibit MAPK kinase 1 or ERK1/ERK2 activation/phosphorylation induced by PMA and mediated by c-Raf. Considering these data, we propose that the inhibition of LPS-induced Cot activation is one mechanism by which 15-deoxy-Δ12,14-prostaglandin J2 acts as an anti-inflammatory. Lipopolysaccharide (LPS) 1The abbreviations used are: LPSlipopolysaccharideERKextracellular signal-regulated kinaseFBSfetal bovine serumGö6850bisindolylmaleimide IHerb Aherbimycin A15d-PGJ215-deoxy-Δ12,14-prostaglandin J2PGE2prostaglandin E2MAPKmitogen-activated protein kinaseMKK1MAPK kinase 1MKKKMAPK kinase kinasePI3Kphosphatidylinositol 3-kinasePKCprotein kinase CPMAphorbol 12-myristate 13-acetatePPAR-γperoxisome proliferator-activated receptor-γTNF-αtumor necrosis factor α.1The abbreviations used are: LPSlipopolysaccharideERKextracellular signal-regulated kinaseFBSfetal bovine serumGö6850bisindolylmaleimide IHerb Aherbimycin A15d-PGJ215-deoxy-Δ12,14-prostaglandin J2PGE2prostaglandin E2MAPKmitogen-activated protein kinaseMKK1MAPK kinase 1MKKKMAPK kinase kinasePI3Kphosphatidylinositol 3-kinasePKCprotein kinase CPMAphorbol 12-myristate 13-acetatePPAR-γperoxisome proliferator-activated receptor-γTNF-αtumor necrosis factor α. is a major cell wall component of Gram-negative bacteria that potently activates macrophages, inducing the production and secretion of immunoregulators such as TNF-α, interleukin-1β, and arachidonic acid metabolites (for reviews see Refs. 1Ulevitch R.J. Tobias P.S. Curr. Opin. Immunol. 1999; 11: 19-22Crossref PubMed Scopus (482) Google Scholar, 2Schletter J. Heine H. Ulmer A.J. Rietschel E.T. Arch. Microbiol. 1995; 164: 383-389Crossref PubMed Scopus (264) Google Scholar, 3Heumann D. Glauser M.P. Calandra T. Curr. Opin. Microbiol. 1998; 1: 49-55Crossref PubMed Scopus (90) Google Scholar). Deregulation of the secretion of these pro-inflammatory cytokines is associated with septic shock and other inflammatory conditions such as rheumatoid arthritis. When complexed with a serum protein, LPS binds to the molecule CD14 on the surface of macrophages. The CD14 receptor itself lacks a cytosolic domain, yet it appears to interact with the toll-like receptors that, in turn, can transduce the signal across the plasma membrane (1Ulevitch R.J. Tobias P.S. Curr. Opin. Immunol. 1999; 11: 19-22Crossref PubMed Scopus (482) Google Scholar, 2Schletter J. Heine H. Ulmer A.J. Rietschel E.T. Arch. Microbiol. 1995; 164: 383-389Crossref PubMed Scopus (264) Google Scholar, 3Heumann D. Glauser M.P. Calandra T. Curr. Opin. Microbiol. 1998; 1: 49-55Crossref PubMed Scopus (90) Google Scholar, 4Andonegui G. Goyert S.M. Kubes P. J. Immunol. 2002; 169: 2111-2119Crossref PubMed Scopus (97) Google Scholar). Indeed, activation of the toll-like receptors triggers an intracellular signaling cascade that involves the adapter proteins MyD 88 and IRAK, and the TRAF6 proteins (for a review see Ref. 5Mak T.W. Yeh W.C. Nature. 2002; 418: 835-836Crossref PubMed Scopus (12) Google Scholar). The LPS signal transduction pathway involves the rapid tyrosine phosphorylation of several proteins and the activation of different mitogen-activated protein kinase (MAPK) cascades, including the classical MAPK pathway (6Weinstein S.L. Sanghera J.S. Lemke K. DeFranco A.L. Pelech S.L. J. Biol. Chem. 1992; 267: 14955-14962Abstract Full Text PDF PubMed Google Scholar, 7Weinstein S.L. Gold M.R. DeFranco A.L. Proc. Natl. Acad. Sci. U. S. A. 1991; 88: 4148-4152Crossref PubMed Scopus (301) Google Scholar, 8Caivano M. FEBS Lett. 1998; 429: 249-253Crossref PubMed Scopus (141) Google Scholar, 9Caivano M. Cohen P. J. Immunol. 2000; 164: 3018-3025Crossref PubMed Scopus (187) Google Scholar). However, the precise molecular mechanism by which LPS activates the extracellular signal-regulated kinases 1 and 2 (ERK1 and ERK2) in the classic MAPK pathway is still not fully understood.The Cot/tpl-2 gene encodes a MAPK kinase kinase (MKKK) that in overexpression studies was originally reported to be capable of triggering several MAPK cascades, namely those leading to activation of the MAPKs ERK1/ERK2, c-Jun N-terminal kinase, p38, and ERK5 (10Salmeron A. Ahmad T.B. Carlile G.W. Pappin D. Narsimhan R.P. Ley S.C. EMBO J. 1996; 15: 817-826Crossref PubMed Scopus (268) Google Scholar, 11Patriotis C. Makris A. Chernoff J. Tsichlis P.N. Proc. Natl. Acad. Sci. U. S. A. 1994; 91: 9755-9759Crossref PubMed Scopus (108) Google Scholar, 12Hagemann D. Troppmair J. Rapp U.R. Oncogene. 1999; 18: 1391-1400Crossref PubMed Scopus (38) Google Scholar, 13Lin X. Cunningham Jr., E.T. Mu Y. Geleziunas R. Greene W.C. Immunity. 1999; 10: 271-280Abstract Full Text Full Text PDF PubMed Google Scholar, 14Chiariello M. Marinissen M.J. Gutkind J.S. Mol. Cell. Biol. 2000; 20: 1747-1758Crossref PubMed Scopus (168) Google Scholar, 15Dumitru C.D. Ceci J.D. Tsatsanis C. Kontoyiannis D. Stamatakis K. Lin J.H. Patriotis C. Jenkins N.A. Copeland N.G. Kollias G. Tsichlis P.N. Cell. 2000; 103: 1071-1083Abstract Full Text Full Text PDF PubMed Scopus (692) Google Scholar). However, more recent studies have shown that peritoneal macrophages from Cot/tpl-2 knockout mice do not activate ERK1/ERK2 in response to LPS, although the activation of c-Jun N-terminal kinase and p38 MAPK pathways remain the same as in wild type mice (15Dumitru C.D. Ceci J.D. Tsatsanis C. Kontoyiannis D. Stamatakis K. Lin J.H. Patriotis C. Jenkins N.A. Copeland N.G. Kollias G. Tsichlis P.N. Cell. 2000; 103: 1071-1083Abstract Full Text Full Text PDF PubMed Scopus (692) Google Scholar). This suggests that under normal conditions, Cot/tpl-2 may act more specifically within the classical MAPK cascade than when overexpressed in cells. Thus, Cot/tpl-2 is one of the three proteins that can activate MAPK kinase 1 (MKK1) in cells, together with Raf and Mos.The Cot/tpl-2 proto-oncogene was originally identified in a modified C-terminally truncated form. The disruption of the last coding exon of the human Cot gene or the truncation of its murine homologue, tpl-2, increases its specific activity (16Ceci J.D. Patriotis C.P. Tsatsanis C. Makris A.M. Kovatch R. Swing D.A. Jenkins N.A. Tsichlis P.N. Copeland N.G. Genes Dev. 1997; 11: 688-700Crossref PubMed Scopus (113) Google Scholar), revealing the oncogenic potential of the gene (16Ceci J.D. Patriotis C.P. Tsatsanis C. Makris A.M. Kovatch R. Swing D.A. Jenkins N.A. Tsichlis P.N. Copeland N.G. Genes Dev. 1997; 11: 688-700Crossref PubMed Scopus (113) Google Scholar, 17Makris A. Patriotis C. Bear S.E. Tsichlis P.N. J. Virol. 1993; 67: 1286-1291Crossref PubMed Google Scholar, 18Miyoshi J. Higashi T. Mukai H. Ohuchi T. Kakunaga T. Mol. Cell. Biol. 1991; 11: 4088-4096Crossref PubMed Scopus (103) Google Scholar). The high levels of Cot expression in malignant human Hodgkin/Reed-Sternberg cells (19Eliopoulos A.G. Davies C. Blake S.S. Murray P. Najafipour S. Tsichlis P.N. Young L.S. J. Virol. 2002; 76: 4567-4579Crossref PubMed Scopus (51) Google Scholar) and human breast cancer cells (20Sourvinos G. Tsatsanis C. Spandidos D.A. Oncogene. 1999; 18: 4968-4973Crossref PubMed Scopus (73) Google Scholar) further emphasize this oncogenic potential. The overexpression of Cot in different cells induces the activation of several transcription factors, including activator protein 1 (12Hagemann D. Troppmair J. Rapp U.R. Oncogene. 1999; 18: 1391-1400Crossref PubMed Scopus (38) Google Scholar, 14Chiariello M. Marinissen M.J. Gutkind J.S. Mol. Cell. Biol. 2000; 20: 1747-1758Crossref PubMed Scopus (168) Google Scholar, 21Ballester A. Velasco A. Tobena R. Alemany S. J. Biol. Chem. 1998; 273: 14099-14106Abstract Full Text Full Text PDF PubMed Scopus (42) Google Scholar), NFAT (22Ballester A. Tobena R. Lisbona C. Calvo V. Alemany S. J. Immunol. 1997; 159: 1613-1618PubMed Google Scholar, 23Tsatsanis C. Patriotis C. Bear S.E. Tsichlis P.N. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 3827-3832Crossref PubMed Scopus (57) Google Scholar, 24de Gregorio R. Iniguez M.A. Fresno M. Alemany S. J. Biol. Chem. 2001; 276: 27003-27009Abstract Full Text Full Text PDF PubMed Scopus (70) Google Scholar), NFκB (13Lin X. Cunningham Jr., E.T. Mu Y. Geleziunas R. Greene W.C. Immunity. 1999; 10: 271-280Abstract Full Text Full Text PDF PubMed Google Scholar, 23Tsatsanis C. Patriotis C. Bear S.E. Tsichlis P.N. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 3827-3832Crossref PubMed Scopus (57) Google Scholar, 25Belich M.P. Salmeron A. Johnston L.H. Ley S.C. Nature. 1999; 397: 363-368Crossref PubMed Scopus (186) Google Scholar, 26Kane L.P. Mollenauer M.N. Xu Z. Turck C.W. Weiss A. Mol. Cell. Biol. 2002; 22: 5962-5974Crossref PubMed Scopus (135) Google Scholar), and E2F (27Velasco-Sampayo A. Alemany S. J. Immunol. 2001; 166: 6084-6090Crossref PubMed Scopus (14) Google Scholar). The involvement of Cot in the secretion of TNF-α in T-cells and macrophages (15Dumitru C.D. Ceci J.D. Tsatsanis C. Kontoyiannis D. Stamatakis K. Lin J.H. Patriotis C. Jenkins N.A. Copeland N.G. Kollias G. Tsichlis P.N. Cell. 2000; 103: 1071-1083Abstract Full Text Full Text PDF PubMed Scopus (692) Google Scholar, 21Ballester A. Velasco A. Tobena R. Alemany S. J. Biol. Chem. 1998; 273: 14099-14106Abstract Full Text Full Text PDF PubMed Scopus (42) Google Scholar) and in the secretion of interleukin-2 in T lymphocytes has also been established (22Ballester A. Tobena R. Lisbona C. Calvo V. Alemany S. J. Immunol. 1997; 159: 1613-1618PubMed Google Scholar, 23Tsatsanis C. Patriotis C. Bear S.E. Tsichlis P.N. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 3827-3832Crossref PubMed Scopus (57) Google Scholar). Furthermore, Cot plays an essential role in inducing transcription of the gene encoding cyclooxygenase-2 (19Eliopoulos A.G. Davies C. Blake S.S. Murray P. Najafipour S. Tsichlis P.N. Young L.S. J. Virol. 2002; 76: 4567-4579Crossref PubMed Scopus (51) Google Scholar, 24de Gregorio R. Iniguez M.A. Fresno M. Alemany S. J. Biol. Chem. 2001; 276: 27003-27009Abstract Full Text Full Text PDF PubMed Scopus (70) Google Scholar). Thus, Cot is a key component in the activation of T-cells and macrophages. Indeed, signals that activate T-cells increase the levels of Cot mRNA, suggesting that the expression of Cot protein increases during the G0 transition of T lymphocytes (28Patriotis C. Makris A. Bear S.E. Tsichlis P.N. Proc. Natl. Acad. Sci. U. S. A. 1993; 90: 2251-2255Crossref PubMed Scopus (147) Google Scholar, 29Sanchez-Gongora E. Lisbona C. de Gregorio R. Ballester A. Calvo V. Perez-Jurado L. Alemany S. J. Biol. Chem. 2000; 275: 31379-31386Abstract Full Text Full Text PDF PubMed Scopus (10) Google Scholar).In this paper we identify two extracellular signals that increase the specific activity of endogenous Cot, namely LPS and Taxol. Furthermore, we demonstrate that Cot is the only MKKK that activates MKK1, and hence ERK1 and ERK2, in macrophages in response to these signals. We also provide evidence that 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2), but not rosiglitazone, blocks the LPS-induced activation of Cot and that it also inhibits Cot activity in vitro. These data indicate that 15d-PGJ2 inhibits LPS-induced Cot activation through a peroxisome proliferator-activated receptor-γ (PPAR-γ)-independent mechanism.EXPERIMENTAL PROCEDURESMaterials—Fetal bovine serum (FBS) was purchased from Invitrogen. Prostaglandin E2 (PGE2), herbimycin A (Herb A), Gö6850 (bisindolylmaleimide I), and 15d-PGJ2 were from Calbiochem; rosiglitazone was a generous gift from GlaxoSmithKline; phorbol 12-myristate 13-acetate (PMA), LPS, sodium orthovanadate, LY 294002, and myelin basic protein were from Sigma; complete proteinase inhibitor mixture was from Roche; and [35S]methionine and [35S]cysteine labeling mixture was from Amersham Biosciences. Taxol (paclitaxel) was generously provided by Dr. Eva López (Bristol-Myers Squibb Co.). Antiphospho-ERK1/ERK2 and anti-ERK2 antibodies were purchased from Zymed Laboratories Inc. Laboratories and anti-phospho-MKK1 plus anti-MKK1 antibodies from Cell Signaling Technology. Antibodies used to immunoprecipitate Cot and c-Raf were raised in sheep against the Cot immunogenic peptide, CQSLDSALFDRKRLLSRKELE, and bacterially expressed c-Raf protein by the Division of Signal Transduction Therapy at the University of Dundee (performed in P. C.'s laboratory). The rabbit anti-Cot antibody utilized for Western blot analysis has been described previously (22Ballester A. Tobena R. Lisbona C. Calvo V. Alemany S. J. Immunol. 1997; 159: 1613-1618PubMed Google Scholar).Cell Culture, Metabolic Labeling, and Stimulation—RAW264 macrophages were maintained in a 95% air, 5% CO2 atmosphere in RPMI plus 10% (v/v) heat-inactivated FBS, 100 units/ml penicillin, 100 μg/ml streptomycin. One day prior to stimulation, macrophages were plated at a density of 1.2 × 106 cells/90-cm plate. Three hours later, the medium was removed and replaced overnight with 8 ml of RPMI with 1% (v/v) heat-inactivated FBS. For metabolic labeling, cells were kept in methionine-, cysteine- and glutamine-free RPMI for 20 min and then pulsed overnight with RPMI plus 1% heat-inactivated FBS dialyzed against phosphate saline buffer plus 100 μCi/ml of [35S]methionine and [35S]cysteine labeling mixture. Unless otherwise indicated, cells were stimulated with 500 ng/ml LPS, 50 μm Taxol, or 0.4 μg/ml PMA for the times specified in the figure legends. Where indicated, 15d-PGJ2 (10 μm), rosiglitazone (10 μm), or PGE2 (5 mm) was added to the medium 60 min before stimulation. Gö6850 (1 μm) and LY 294002 (50 μm) were added to the medium 30 min before stimulation and Herb A (1 μg/ml) 3 h before stimulation.Immunoprecipitation and Assay of Cot and c-Raf—After stimulation, the medium was removed, and the cells were solubilized in 0.5 ml of ice cold lysis buffer (50 mm Tris acetate (pH 7.0), 1 mm EDTA, 1 mm EGTA, 1% (w/v) Triton X-100, 1 mm sodium orthovanadate, 10 mm sodium glycerophosphate, 50 mm NaF, 5 mm sodium pyrophosphate, 0.27 m sucrose, 0.1% (v/v) 2-mercaptoethanol, and complete proteinase inhibitor mixture, 1 tablet/10 ml). The samples were then frozen in liquid nitrogen and stored in aliquots at -70 °C until analysis. Cell extracts were thawed at 0 °C and centrifuged for 10 min at 24,000 × g, and protein concentration was determined by the Bradford method. The protein c-Raf was immunoprecipitated for 1 h at 4 °C by incubating 0.5 mg of cell lysate protein with 1 μg of c-Raf antibody that had been coupled to protein G-Sepharose. Cot was immunoprecipitated for 3 h at 4 °C by incubating 0.5 mg of cell lysate protein with 1.5 μg of Cot antibody covalently bound to protein G-Sepharose. The different immunoprecipitates were washed and subjected to a two-step kinase assay as described previously for c-Raf (30Alessi D.R. Cohen P. Ashworth A. Cowley S. Leevers S.J. Marshall C.J. Methods Enzymol. 1995; 255: 279-290Crossref PubMed Scopus (155) Google Scholar). One unit of Cot or c-Raf activity was that amount of enzyme that incorporated 1 nmol of phosphate into myelin basic protein in 1 min.Western Blot Analysis—Western blotting was performed by resolving 35 μg of cell lysate protein on 10% SDS-polyacrylamide gels. The proteins were transferred to polyvinylidene difluoride membranes and probed with anti-phospho-ERK1/ERK2 or anti-phospho-MKK1 antibodies. The blots were developed using a chemiluminescent method (ECL, Amersham Biosciences). As a control of protein loading on the gels, the polyvinylidene difluoride membranes were re-probed with anti-ERK2 or anti-MKK1 antibodies.RESULTSLPS and Taxol Activate Cot but Not c-Raf—Treatment of RAW264 macrophages with LPS (500 ng/ml) produced a time-dependent activation of endogenous Cot activity (Fig. 1). Maximal activation reached about 10-fold the basal levels and was attained 15 min after the addition of LPS. In contrast, LPS stimulation did not augment the activity of c-Raf. Because Taxol is reported to mimic LPS-induced activation of murine macrophages through an interaction with CD14 (31Kawasaki K. Nogawa H. Nishijima M. J. Immunol. 2003; 170: 413-420Crossref PubMed Scopus (72) Google Scholar, 32Moos P.J. Muskardin D.T. Fitzpatrick F.A. J. Immunol. 1999; 162: 467-473PubMed Google Scholar, 33O'Brien Jr., J.M. Wewers M.D. Moore S.A. Allen J.N. J. Immunol. 1995; 154: 4113-4122PubMed Google Scholar), we also examined the effect of stimulating RAW264.7 macrophages with 50 μm Taxol for different time periods on Cot and c-Raf activity. Not only did Taxol increase the specific activity of endogenous Cot, although to a lesser extent than LPS, but also Taxol failed to up-regulate c-Raf activity (Fig. 1).PMA Activates c-Raf but Not Cot—It has been well established that through protein kinase C (PKC), the tumor-promoting phorbol esters can trigger the activation of the classical MAPK cascade in a wide variety of cells, including macrophages. We therefore set out to compare the mechanism by which PMA and LPS activate this signaling pathway in macrophages. Stimulation of RAW264 cells with 0.4 μg/ml PMA increased c-Raf activity about 10-fold, with the maximal increase occurring 5 min after stimulation. However, in sharp contrast to LPS or Taxol, PMA did not activate Cot activity (Fig. 1), indicating that PMA and LPS/Taxol activate the MAPK cascade in different ways.The Mechanism by Which LPS Activates Cot—In Western blots of endogenous immunoprecipitated Cot, a single band that migrated in the position expected for the Cot polypeptide was observed (Fig. 2A). On this basis, we assessed the possibility that LPS increased Cot activity by modulating its association/dissociation with putative regulatory subunit(s). Unstimulated and LPS-stimulated cells were labeled with [35S]methionine and [35S]cysteine, and endogenous Cot was immunoprecipitated from the cell lysates. The immunoprecipitated proteins were separated by SDS-polyacrylamide gel electrophoresis, and subsequent autoradiography revealed a single radiolabeled band of the expected size for Cot (Fig. 2B). The absence of any other labeled protein implied that Cot activation by LPS does not result from its association with, or dissociation from, any other protein.Fig. 2Immunoprecipitation of endogenous Cot from RAW264 macrophages stimulated or not with LPS.A, Cot immunoprecipitated from control cell lysates (250 μg) was subjected to Western blot analysis with rabbit anti-Cot antibody. B, 35S-labeled RAW cells were stimulated or not stimulated with 500 ng/ml LPS for 15 min. Cot was immunoprecipitated from the different RAW cells extracts in the presence or absence of 10 mm immunogenic peptide and resolved by SDS-polyacrylamide gel electrophoresis followed by autoradiography and radioactivity quantification by Instant Imager. The figure shows one of three experiments performed.View Large Image Figure ViewerDownload Hi-res image Download (PPT)Another possible mechanism for Cot activation might involve its phosphorylation at one or more residues. However, treatment of Cot immunoprecipitated from LPS-stimulated cells with high concentrations of the catalytic subunit of protein phosphatases 1 or 2A or protein tyrosine phosphatase 1B did not affect the activity of Cot (data not shown). Moreover, the inhibition of serine/threonine phosphatases PP1 or PP2A, potential regulators of Cot phosphorylation, by incubating RAW cells with okadaic acid, did not increase Cot activity (data not shown). Finally, we also transfected Cot into HEK293 cells, which were then stimulated with the protein tyrosine phosphatase inhibitor orthovanadate, or with orthovanadate plus okadaic acid. However, neither of these treatments increased the activity of Cot (data not shown). Taken together, these data indicate that it is unlikely that serine/threonine phosphorylation of Cot is responsible for the way in which LPS influences its level of activity.Inhibitors of Protein Tyrosine Kinases Block the Activation of Cot by LPS—Herb A is an irreversible inhibitor of protein tyrosine kinases, and it has been found to block both LPS-stimulated tyrosine phosphorylation and the activation of ERK1/ERK2 in macrophages (6Weinstein S.L. Sanghera J.S. Lemke K. DeFranco A.L. Pelech S.L. J. Biol. Chem. 1992; 267: 14955-14962Abstract Full Text PDF PubMed Google Scholar). Therefore, we analyzed the effects that this inhibitor might have on Cot activation. Preincubating RAW264 cells with Herb A prevented the activation of Cot by LPS or Taxol (Fig. 3A), although the same treatment did not affect the activation of c-Raf by PMA. Furthermore, Herb A inhibited the activation of MKK1 and ERK1/ERK2 by LPS or Taxol but not by PMA (Fig. 3B). Similar results were also obtained when Herb A was replaced by genistein or tyrphostin AG825, other protein tyrosine kinase inhibitors not structurally related to Herb A (data not shown).Fig. 3Herb A inhibits Cot activation by LPS. Macrophages were preincubated with Herb A (1 μg/ml) for 3 h and then stimulated with LPS (200 ng/ml) for 15 min, with Taxol (50 μm) for 20 min, or with PMA (0.4 μg/ml) for 5 min. A, Cot or c-Raf was immunoprecipitated from different LPS-, Taxol-, or PMA-treated cells, and MKK1 kinase activity was measured. The results are represented as the mean ± S.E. for three different determinations from two separate dishes. The value 1 corresponds to Cot or c-Raf activities from control cells. B, lysates of the differently treated cells were electrophoresed and immunoblotted with anti-phospho-ERK1/ERK2 and anti-phospho-MKK1 antibodies. As a control of protein loaded, total ERK2 and total MKK1 levels, respectively, were tested. Similar results were obtained in three different experiments.View Large Image Figure ViewerDownload Hi-res image Download (PPT)The Activation of Cot by LPS Is Independent of Phosphatidylinositol 3-Kinase and Protein Kinase C—It has been reported that protein kinase B, which is activated “downstream” of phosphatidylinositol 3-kinase (PI3K), induces the phosphorylation of the C terminus of Cot and that this event is accompanied by an increase in NF-κB activation (26Kane L.P. Mollenauer M.N. Xu Z. Turck C.W. Weiss A. Mol. Cell. Biol. 2002; 22: 5962-5974Crossref PubMed Scopus (135) Google Scholar). However, the preincubation of RAW264 cells for 30 min with an inhibitor of PI3K, LY 294002 (50 μm), did not block the phosphorylation of ERK1/ERK2 or MKK1 upon stimulation with LPS or PMA (data not shown). Moreover, co-transfection of an active form of PI3K together with Cot in HEK293 cells did not increase the activity of Cot, whether or not the cells were exposed to orthovanadate (data not shown). Protein kinase Cϵ (PKCϵ) has been reported to play a critical role in macrophage activation and in the generation of TNF-α (34Castrillo A. Pennington D.J. Otto F. Parker P.J. Owen M.J. Bosca L. J. Exp. Med. 2001; 194: 1231-1242Crossref PubMed Scopus (203) Google Scholar). Because Cot also participates in TNF-α secretion (15Dumitru C.D. Ceci J.D. Tsatsanis C. Kontoyiannis D. Stamatakis K. Lin J.H. Patriotis C. Jenkins N.A. Copeland N.G. Kollias G. Tsichlis P.N. Cell. 2000; 103: 1071-1083Abstract Full Text Full Text PDF PubMed Scopus (692) Google Scholar, 21Ballester A. Velasco A. Tobena R. Alemany S. J. Biol. Chem. 1998; 273: 14099-14106Abstract Full Text Full Text PDF PubMed Scopus (42) Google Scholar), we decided to evaluate the role that PKCϵ plays in regulating activation of the classic MAPK cascade via LPS and PMA. As expected, incubation of RAW cells with Gö6850, an inhibitor of PKCα, PKCβ1, PKCδ, and PKCϵ, blocked the PMA-induced activation of c-Raf, MKK1, and ERK1/ERK2. However, preincubation with Gö6850 did not affect the LPS-induced activation of Cot or the phosphorylation of MKK1 and ERK1/ERK2 (Fig. 4), indicating that neither PI3K nor PKCϵ is involved in the activation of Cot by LPS.Fig. 4Gö6850 does not inhibit Cot activation by LPS. Macrophages were preincubated with Gö6850 (1 μm) for 30 min and then stimulated with LPS (200 ng/ml) for 15 min or with PMA (0.4 μg/ml) for 5 min. The phosphorylation states of ERK1/ERK2 and MKK1 (A) and Cot or c-Raf activities (B) were measured as described under “Experimental Procedures.” The value 100% corresponds to Cot or c-Raf activities when cells were stimulated, respectively, with LPS or PMA. The figure shows one of three experiments performed, and the graph represents the mean of three different determinations ± S.E.View Large Image Figure ViewerDownload Hi-res image Download (PPT)15d-PGJ2Blocks the Activation of Cot by LPS—Ligands of PPAR-γ are negative regulators of macrophage activation (35Alleva D.G. Johnson E.B. Lio F.M. Boehme S.A. Conlon P.J. Crowe P.D. J. Leukocyte Biol. 2002; 71: 677-685PubMed Google Scholar, 36Ricote M. Li A.C. Willson T.M. Kelly C.J. Glass C.K. Nature. 1998; 391: 79-82Crossref PubMed Scopus (3239) Google Scholar, 37Straus D.S. Pascual G. Li M. Welch J.S. Ricote M. Hsiang C.H. Sengchanthalangsy L.L. Ghosh G. Glass C.K. Proc. Natl. Acad. Sci. U. S. A. 2000; 97: 4844-4849Crossref PubMed Scopus (939) Google Scholar, 38Thieringer R. Fenyk-Melody J.E. Le Grand C.B. Shelton B.A. Detmers P.A. Somers E.P. Carbin L. Moller D.E. Wright S.D. Berger J. J. Immunol. 2000; 164: 1046-1054Crossref PubMed Scopus (187) Google Scholar, 39Su C.G. Wen X. Bailey S.T. Jiang W. Rangwala S.M. Keilbaugh S.A. Flanigan A. Murthy S. Lazar M.A. Wu G.D. J. Clin. Investig. 1999; 104: 383-389Crossref PubMed Scopus (720) Google Scholar). Preincubation of RAW264 macrophages with 15d-PGJ2 (10 μm), a potent natural ligand of PPAR-γ, completely suppressed the activation of Cot by LPS or Taxol (Fig. 5A). Consistent with this finding, when cells were preincubated with 15d-PGJ2, neither MKK1 nor ERK1/ERK2 were activated by LPS. Nevertheless preincubation with 15d-PGJ2 did not decrease the levels of LPS-induced tyrosine phosphorylation as determined by Western blot analysis (data not shown). On the other hand, neither the PMA-induced activation of c-Raf nor the PMA-induced phosphorylation of MKK1 and ERK1/ERK2 was affected by preincubation with 15d-PGJ2 (Fig. 5A).Fig. 515d-PGJ2 inhibits ERK1/ERK2 activation via Cot in RAW macrophages.A, RAW264 macrophages were preincubated with 15d-PGJ2 (PGJ2, 10 μm) for 60 min and then stimulated with LPS for 15 min (200 ng/ml), with Taxol (50 μm) for 20 min, or with PMA for 5 min (0.4 μg/ml), and the phosphorylation state of ERK1/ERK2 and MKK1, as well as Cot or c-Raf activities, was determined. The figure shows one of three experiments performed, and the graphs represent the mean of three different determinations ± S.E. The value 1 corresponds to Cot or c-Raf activities from control cells. B, RAW264 macrophages were preincubated with PGE2 (5 mm) or rosiglitazone (Ros, 10 μm) for 60 min and then stimulated with LPS (200 ng/ml) for 15 min, and Cot activity was determined. The graph represents the mean of three different determinations ± S.E. The value 100% correspond to Cot activity from LPS-activated cell lysates. C, Cot or c-Raf was immunoprecipitated from macrophages stimulated, respectively, with LPS or PMA. The MKK1 kinase activity of the different MKKKs was measured in the presence or absence of 10 μm 15d-PGJ2. The results are represented as the mean ± S.E. for two different determinations from three separate dishes. The value 100% corresponds to Cot or c-Raf activities assayed in the absence of 15d-PGJ2.View Large Image Figure ViewerDownload Hi-res image Download (PPT)To address the specificity of 15d-PGJ2, RAW macrophages were also pre-incubated with 5 mm PGE2 prior to stimulation with LPS. Exposure to PGE2 did not inhibit the LPS-induced activation of Cot (Fig. 5B). Furthermore, we analyzed the effect of rosiglitazone, a synthetic PPAR-γ ligand with an affinity that is equal to or exceeds the affinity of 15d-PGJ2 (4" @default.
• W2095297787 created "2016-06-24" @default.
• W2095297787 creator A5010890113 @default.
• W2095297787 creator A5016349252 @default.
• W2095297787 creator A5056050624 @default.
• W2095297787 creator A5057659086 @default.
• W2095297787 date "2003-12-01" @default.
• W2095297787 modified "2023-10-17" @default.
• W2095297787 title "15-Deoxy-Δ12,14-prostaglandin J2 Regulates Endogenous Cot MAPK Kinase Kinase 1 Activity Induced by Lipopolysaccharide" @default.
• W2095297787 cites W111392919 @default.
• W2095297787 cites W1490521893 @default.
• W2095297787 cites W1539392991 @default.
• W2095297787 cites W1558190734 @default.
• W2095297787 cites W1579092429 @default.
• W2095297787 cites W1586373415 @default.
• W2095297787 cites W1590494234 @default.
• W2095297787 cites W1633340712 @default.
• W2095297787 cites W1639924204 @default.
• W2095297787 cites W1671728707 @default.
• W2095297787 cites W1757025193 @default.
• W2095297787 cites W1779302679 @default.
• W2095297787 cites W1812573520 @default.
• W2095297787 cites W1925208150 @default.
• W2095297787 cites W1968241763 @default.
• W2095297787 cites W1975215292 @default.
• W2095297787 cites W1980605688 @default.
• W2095297787 cites W1988886903 @default.
• W2095297787 cites W1989503423 @default.
• W2095297787 cites W2001192666 @default.
• W2095297787 cites W2003115027 @default.
• W2095297787 cites W2014603866 @default.
• W2095297787 cites W2023404740 @default.
• W2095297787 cites W2025564450 @default.
• W2095297787 cites W2027152576 @default.
• W2095297787 cites W2034658941 @default.
• W2095297787 cites W2038470330 @default.
• W2095297787 cites W2042618169 @default.
• W2095297787 cites W2043544340 @default.
• W2095297787 cites W2059786080 @default.
• W2095297787 cites W2062910628 @default.
• W2095297787 cites W2063956233 @default.
• W2095297787 cites W2067387401 @default.
• W2095297787 cites W2080270051 @default.
• W2095297787 cites W2091694934 @default.
• W2095297787 cites W2111667226 @default.
• W2095297787 cites W2113709051 @default.
• W2095297787 cites W2113737578 @default.
• W2095297787 cites W2117054107 @default.
• W2095297787 cites W2120872807 @default.
• W2095297787 cites W2124655831 @default.
• W2095297787 cites W2139997445 @default.
• W2095297787 cites W2158318101 @default.
• W2095297787 cites W2158998343 @default.
• W2095297787 cites W2164171309 @default.
• W2095297787 cites W2324000374 @default.
• W2095297787 cites W2324752099 @default.
• W2095297787 cites W4240789623 @default.
• W2095297787 cites W4362204104 @default.
• W2095297787 cites W49625740 @default.
• W2095297787 doi "https://doi.org/10.1074/jbc.m306583200" @default.
• W2095297787 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14557273" @default.
• W2095297787 hasPublicationYear "2003" @default.
• W2095297787 type Work @default.
• W2095297787 sameAs 2095297787 @default.
• W2095297787 citedByCount "28" @default.
• W2095297787 countsByYear W20952977872012 @default.
• W2095297787 countsByYear W20952977872013 @default.
• W2095297787 countsByYear W20952977872014 @default.
• W2095297787 countsByYear W20952977872015 @default.
• W2095297787 countsByYear W20952977872017 @default.
• W2095297787 countsByYear W20952977872019 @default.
• W2095297787 crossrefType "journal-article" @default.
• W2095297787 hasAuthorship W2095297787A5010890113 @default.
• W2095297787 hasAuthorship W2095297787A5016349252 @default.
• W2095297787 hasAuthorship W2095297787A5056050624 @default.
• W2095297787 hasAuthorship W2095297787A5057659086 @default.
• W2095297787 hasBestOaLocation W20952977871 @default.
• W2095297787 hasConcept C134018914 @default.
• W2095297787 hasConcept C16613235 @default.
• W2095297787 hasConcept C184235292 @default.
• W2095297787 hasConcept C185592680 @default.
• W2095297787 hasConcept C2778754761 @default.
• W2095297787 hasConcept C55493867 @default.
• W2095297787 hasConcept C57074206 @default.
• W2095297787 hasConcept C86803240 @default.
• W2095297787 hasConcept C95444343 @default.
• W2095297787 hasConcept C97029542 @default.
• W2095297787 hasConceptScore W2095297787C134018914 @default.
• W2095297787 hasConceptScore W2095297787C16613235 @default.
• W2095297787 hasConceptScore W2095297787C184235292 @default.
• W2095297787 hasConceptScore W2095297787C185592680 @default.
• W2095297787 hasConceptScore W2095297787C2778754761 @default.
• W2095297787 hasConceptScore W2095297787C55493867 @default.
• W2095297787 hasConceptScore W2095297787C57074206 @default.
• W2095297787 hasConceptScore W2095297787C86803240 @default.
• W2095297787 hasConceptScore W2095297787C95444343 @default.
• W2095297787 hasConceptScore W2095297787C97029542 @default.
• W2095297787 hasIssue "52" @default.

• next